| |
| |
|
| Insider
Information: |
Greenleaf Peter |
| Relationship: |
Chief Executive Office... |
| City: |
Gaithersburg |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
1,634,614 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,521,966 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,634,614 |
|
|
| Total
Value |
$7,521,966 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-3.0
|
| Percentage
Gain/Loss : |
 48.4%
|
 -79.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sucampo Pharmaceuticals, Inc. |
SCMP |
Chief Executive Officer |
2018-02-13 |
0 |
2015-12-31 |
0 |
Premium* |
|
|
Avalo Therapeutics, Inc |
AVTX |
Director |
2019-05-24 |
112,500 |
2018-03-27 |
0 |
Premium* |
|
|
Biodelivery Sciences Internation... |
BDSI |
Director |
2022-03-22 |
0 |
2018-08-14 |
0 |
Premium* |
|
|
Antares Pharma Inc |
ATRS |
Director |
2022-05-24 |
0 |
2019-06-13 |
0 |
Premium* |
|
|
Aurinia Pharmaceuticals Inc |
AUPH |
Chief Executive Office... |
2024-03-06 |
1,522,114 |
2021-05-11 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-03-06 |
4 |
S |
$5.60 |
$711,094 |
D/D |
(126,981) |
1,522,114 |
0 |
% |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
661,538 |
1,649,095 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-03-02 |
4/A |
S |
$8.78 |
$290,153 |
D/D |
(33,047) |
982,671 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-03-02 |
4 |
S |
$8.94 |
$292,785 |
D/D |
(32,750) |
982,968 |
0 |
% |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
667,407 |
1,015,718 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2022-05-24 |
4 |
D |
$5.60 |
$446,012 |
D/D |
(79,645) |
0 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2022-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(105,034) |
0 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2022-03-02 |
4 |
S |
$12.01 |
$108,907 |
D/D |
(9,068) |
32,967 |
0 |
% |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
28,300 |
42,035 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2022-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,246 |
105,034 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2021-08-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
94,788 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2021-06-10 |
4 |
A |
$4.42 |
$112,498 |
D/D |
25,452 |
79,645 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Chief Executive Officer |
• • – |
2021-05-11 |
4 |
B |
$10.15 |
$54,891 |
D/D |
5,125 |
13,453 |
2.81 |
% |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2020-08-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
59,788 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2020-06-11 |
4 |
A |
$2.73 |
$82,501 |
D/D |
30,220 |
54,193 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2019-08-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,144 |
24,788 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Director |
– • – |
2019-06-13 |
4 |
A |
$2.92 |
$70,001 |
D/D |
23,973 |
23,973 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Director |
– • – |
2019-05-24 |
4 |
D |
$0.00 |
$0 |
D/D |
(300,000) |
112,500 |
0 |
- |
|
| BDSI |
Biodelivery Sciences Inte... |
Director |
– • – |
2018-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,644 |
3,644 |
0 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Executive Officer |
• • – |
2018-05-18 |
4 |
B |
$3.98 |
$49,750 |
D/D |
12,500 |
412,500 |
2.81 |
- |
|
| AVTX |
Avalo Therapeutics, Inc |
Chief Executive Officer |
• • – |
2018-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
400,000 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Chief Executive Officer |
• – – |
2018-02-13 |
4 |
D |
$18.00 |
$2,335,122 |
D/D |
(129,729) |
0 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
Chief Executive Officer |
• – – |
2017-12-31 |
4 |
A |
$9.10 |
$1,556 |
D/D |
171 |
4,792 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
CEO |
• – – |
2017-09-30 |
4 |
A |
$9.10 |
$5,997 |
D/D |
659 |
4,621 |
0 |
- |
|
| SCMP |
Sucampo Pharmaceuticals, ... |
CEO |
• – – |
2017-06-30 |
4 |
A |
$8.93 |
$6,010 |
D/D |
673 |
3,962 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
